Menu
← Oncology Approval Tracker
FDA DECISION ·
Ibrance + anti-HER2 therapy
palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy · Pfizer
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Maintenance for adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer after induction therapy.
LAMPGEN ANALYSIS
Why it matters
PATINA tested CDK4/6 inhibition in maintenance after induction in a dual receptor-positive population. The maintenance setting and receptor combination define what the data can inform.
What research teams should watch
At the maintenance transition, confirm induction completion, absence of progression and both receptor results. Align hematology monitoring with HER2-directed and endocrine therapy.
PRIMARY RECORDS